The next head of Novo Nordisk’s European business is likely to come from outside the company ranks, but CEO Lars Fruergaard is in no rush to find the executive to take up his old position. Increased uncertainty in the US means the group is preparing for a dip in sales for the first time in decades.
BY STEFAN SINGH KAILAY Offentliggjort 08.02.17 kl. 09:22
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Søren Nielsen, who was one of the founders of Action Pharma, has quietly been building a new company that he expects to offload to Big Pharma by the close of 2015. There are, however, still a couple of challenges on the way.
For the third time, Novo A/S invests in Synlab, Europe’s biggest company for laboratory analyses. Previously, Novo A/S has not wanted to disclose the amount invested. But this time, the investment sum is revealed and it amounts to billions of Danish kroner.
Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.
Novo Nordisk fører an i jagten på at udvikle medicin, som kan smelte kilo af overvægtige kroppe. Spritnye resultater for GLP-1-analogen Semaglutid viser de første gode takter for medicinalkoncernens næste fedmehåb. (opdateret)
Om Lundbeck vil forsøge en tredje gang at få udvidet indlægssedlen på antidepressivet Trintellix i USA er endnu uvist, siger forskningsdirektør Anders Gersel Pedersen for hvem, nattens afslag fra FDA ikke var en fuldstændig overraskelse.